<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818739</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-12114</org_study_id>
    <secondary_id>NCI-2013-00530</secondary_id>
    <nct_id>NCT01818739</nct_id>
  </id_info>
  <brief_title>Lymph Node Mapping in Patients With Endometrial Cancer</brief_title>
  <official_title>Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies lymph node mapping in patients with endometrial cancer. Lymph&#xD;
      node mapping may allow for limited removal of lymph nodes in as part of endometrial cancer&#xD;
      staging and treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the negative predictive value of pelvic sentinel lymph node (SLN) in&#xD;
      endometrial cancer to predict nodal metastasis.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      II. To examine the ability of sentinel lymph nodes to increase the detection of metastatic&#xD;
      disease through ultra-sectioning and immuno-histochemical (IHC) staining by comparing IHC&#xD;
      results and standard hematoxylin and eosin (H&amp;E) results.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine&#xD;
      green solution and isosulfan blue and sentinel lymph node biopsy and detection of sentinel&#xD;
      lymph nodes is noted in the within 30 minutes of injection of the dye, followed by full&#xD;
      pelvic lymph node dissection and aortic lymph node dissection as indicated, and standard&#xD;
      hysterectomy and salpingo-oophorectomy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      every 6 months for 3 years for a total of 5 years according to the standard surveillance&#xD;
      guidelines for endometrial cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">November 16, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease</measure>
    <time_frame>average of 1-14 days after the procedure when final pathologic evaluation has been completed</time_frame>
    <description>NPV is found by dividing the number of true negatives by the number of all patients without pelvic lymph node metastases. Exact 95% confidence intervals (CIs) for the proportions will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining</measure>
    <time_frame>average of 1-14 days after the procedure when final pathologic evalulation has been completed</time_frame>
    <description>The percentage of metastatic cases analyzed by H&amp;E will be compared to those of H&amp;E-plus- IHC/ultrastaging using a &quot;z-test&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node detection</intervention_name>
    <description>Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green solution</intervention_name>
    <description>Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <other_name>IC-GREEN</other_name>
    <other_name>ICG solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosulfan blue</intervention_name>
    <description>Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <other_name>Lymphazurin</other_name>
    <other_name>N-[4-[4-(diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
    <description>Undergo sentinel lymph node biopsy</description>
    <arm_group_label>sentinel lymph node detection</arm_group_label>
    <other_name>sentinel node biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be willing and able to provide informed consent&#xD;
&#xD;
          -  The patient is willing and able to comply with the study protocol&#xD;
&#xD;
          -  The patient has endometrial cancer and is scheduled for robotic hysterectomy and&#xD;
             lymphadenectomy&#xD;
&#xD;
          -  The patient agrees to follow-up examinations out to 5-years post-treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is not a candidate for robotic assisted hysterectomy and lymphadenectomy&#xD;
&#xD;
          -  The patient has known or suspected allergies to iodine, indocyanine green (ICG) or&#xD;
             isosulfan blue (ISB)&#xD;
&#xD;
          -  The patient has hepatic dysfunction confirmed by bilirubin &gt; 2 x normal (based on&#xD;
             reference values from the laboratory used by the patient)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Floor Backes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <reference>
    <citation>Backes FJ, Cohen D, Salani R, Cohn DE, O'Malley DM, Fanning E, Suarez AA, Fowler JM. Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol. 2019 Jun;153(3):496-499. doi: 10.1016/j.ygyno.2019.03.252. Epub 2019 Apr 4.</citation>
    <PMID>31230614</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Floor Backes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Robotic-Assisted Staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened in February 2013 and patients were enrolled between March 2013 and November 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sentinel Lymph Node Detection</title>
          <description>Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients received dye injections</population>
      <group_list>
        <group group_id="B1">
          <title>Sentinel Lymph Node Detection</title>
          <description>Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="30" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" lower_limit="18.2" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease</title>
        <description>NPV is found by dividing the number of true negatives by the number of all patients without pelvic lymph node metastases. Exact 95% confidence intervals (CIs) for the proportions will be calculated.</description>
        <time_frame>average of 1-14 days after the procedure when final pathologic evaluation has been completed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Lymph Node Detection</title>
            <description>Patients with negative SLN who underwent sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease</title>
          <description>NPV is found by dividing the number of true negatives by the number of all patients without pelvic lymph node metastases. Exact 95% confidence intervals (CIs) for the proportions will be calculated.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="95.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining</title>
        <description>The percentage of metastatic cases analyzed by H&amp;E will be compared to those of H&amp;E-plus- IHC/ultrastaging using a &quot;z-test&quot;.</description>
        <time_frame>average of 1-14 days after the procedure when final pathologic evalulation has been completed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Lymph Node Detection</title>
            <description>Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining</title>
          <description>The percentage of metastatic cases analyzed by H&amp;E will be compared to those of H&amp;E-plus- IHC/ultrastaging using a &quot;z-test&quot;.</description>
          <units>percentage of patients with positive LN</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sentinel Lymph Node Detection</title>
          <description>Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Floor Backes, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-730-6968</phone>
      <email>Floor.Backes@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

